Showing results (11-20 of 68) with videos related to
Sort By:
Pageof 7
Expert Opinion on Investigational Drugs|July 2, 2003
Thalidomide: a new anticancer drug?Massimo Fanelli, Roberta Sarmiento, Domenico Gattuso, et al.The Oncologist|October 27, 2005
Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancerGiampietro Gasparini, Domenico Gattuso, Alessandro Morabito, et al.Expert Opinion on Therapeutic Targets|November 15, 2011
The paradigm of personalized therapy in oncologyGiampietro Gasparini, Raffaele LongoExpert Review of Molecular Diagnostics|July 5, 2008
Anti-VEGF therapy: the search for clinical biomarkersRaffaele Longo, Giampietro GaspariniNature Clinical Practice. Oncology|July 3, 2008
Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applicationsGiampaolo Tortora, Fortunato Ciardiello, Giampietro GaspariniCurrent Pharmaceutical Design|March 14, 2007
Targeted therapy of breast cancerRaffaele Longo, Francesco Torino, Giampietro GaspariniNature Clinical Practice. Oncology|November 5, 2005
Angiogenic inhibitors: a new therapeutic strategy in oncologyGiampietro Gasparini, Raffaele Longo, Masakazu Toi, et al.Cancer Journal (Sudbury, Mass.)|August 2, 2005
Thalidomide is inactive in heavily pretreated patients with metastatic breast cancerAlessandro Morabito, Guido Carillio, Raffaele Longo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questionsGiampietro Gasparini, Raffaele Longo, Massimo Fanelli, et al.Breast Cancer Research and Treatment|November 30, 2004
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancerAlessandro Morabito, Domenico Gattuso, Simonetta Chiara Stani, et al.Pageof 7